Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly EBT Margin of 440356600.0% for Q4 2023, down 44034978036.0% year-over-year from N/an in Q4 2022, and down 7297886.32% quarter-over-quarter from 6033.95% in Q3 2023.
Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported EBT Margin for 4 consecutive years, with 440356600.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, EBT Margin fell 44034978036.0% year-over-year to 440356600.0%; the TTM figure through Sep 2024 stood at 2042608500.0% (down 204260228406.0% YoY), while the FY2023 annual figure was 7712.68%, up 1700723.0% from the prior year.
- EBT Margin retreated to 440356600.0% in Q4 2023 per IKT's latest filing, from 6033.95% in the prior quarter.
- Across five years, EBT Margin topped out at 187.4% in Q1 2021 and bottomed at 440356600.0% in Q4 2023.
- Historically, EBT Margin has averaged 27549295.07% across 4 years, with a median of 5698.43% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin surged 25156518 bps — and 2023, when it tumbled 2000000000 bps.
- Inhibikase Therapeutics' EBT Margin stood at 708.85% in 2020, then plunged by 36352 bps to 258384.83% in 2021, then surged by 97 bps to 6819.64% in 2022, then sank by 6457080 bps to 440356600.0% in 2023.
- Business Quant data shows IKT's EBT Margin at 440356600.0% in Q4 2023, 6033.95% in Q3 2023, and 5362.92% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -6,033.95% |
| Jun 30, 2023 | -5,362.92% |
| Mar 31, 2023 | -7,384.64% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -62,609.53% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,083.57% |
| Dec 31, 2021 | -258,384.83% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
| Sep 30, 2020 | -1,779.72% |
| Jun 30, 2020 | -192.12% |
| Mar 31, 2020 | -202.17% |